#3 – Pfizer (PFE)
Drug manufacturer Pfizer (NYSE: PFE) has had a rough go of it in 2010. The company’s stock has fallen -12.4% since January, despite beating earnings estimates three of the last four quarters. While the stock may be down, shareholders can still bank on the large 4.4% dividend yield they will be receiving on Sept. 1. In a bit of good news for Pfizer, a recent lawsuit claiming that the company’s menopause drug caused cancer in two women was dismissed. A contrary ruling would have been bad news for Pfizer’s stock, and fortunately for the company and its clients, the drug was ruled not to have had the damaging affect on patients. |
|














Comments are currently unavailable. Please check back soon.